LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis
Shots:
- LEO Pharma has submitted NDA of Enstilar to the NMPA for treating adults with plaque psoriasis. The review process is expected to conclude by the H1’26
- The NDA submission was based on P-III study assessing the safety & efficacy of Enstilar vs Daivobet ointment post 4wks. treatment among adult Chinese patients (n=604) with plaque psoriasis. It reached its 1 & 2EPs, showing superior effectiveness & safety of Enstilar
- Enstilar is an aerosol spray foam comprising of calcipotriol monohydrate (50mcg/g) & betamethasone dipropionate (0.5mg/g). It is approved in the EU for treating psoriasis vulgaris in adults for over 4wks., with long-term maintenance for responsive patients
Ref: LEO Pharma | Image: LEO Pharma
Related News: LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
